You are here: Industry Insights > Vivimed

News List

Vivimed exports its first shipment, Famotidine tablets, to Canada expresspharma
May 25, 2021
Vivimed Labs, a niche speciality chemicals and pharma company, announced the export of its first shipment to Canada – Famotidine tablets 40 mg and 20 mg manufactured in its Vivimed Hyderabad site which is approved by Health CANADA.
Vivimed gets DGHI nod to manufacture, market favipiravir tablet in India expresspharma
May 11, 2021
Vivimed Labs announced the receipt of Government of India (Director General of Health Services) approval to manufacture and market Favipiravir Tablet 200 mg and 400 mg under Vivimed’s own brand name ‘Favulous’ across India.
Vivimed Labs gets approval for one product from Uzbekistan expresspharma
February 23, 2021
The approval is for Paracetamol 125mg/5mL + Chlorpheniramine Maleate 2.5 mg/5mL syrup to be sold under brand name, FEBRIL Syrup 100 ml.
Vivimed Life Sciences Pvt Ltd Issues Voluntary Nationwide Recall of Losartan Potassium 25 mg, 50 mg and 100 mg Tablets, USP Due to the Detection of Trace Amounts of N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) Impurity drugs
May 20, 2019
Vivimed Life Sciences Pvt Ltd Issues Voluntary Nationwide Recall of Losartan Potassium 25 mg, 50 mg and 100 mg Tablets, USP Due to the Detection of Trace Amounts of N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) Impurity.
Strides to acquire remaining stake in Vivimed biospectrumasia
January 31, 2019
Complements Strides’s front end led growth with a de-risked manufacturing base.